相似文献
1
Urgent hemodialysis induced an acute gout attack in a patient with multiple tophi: report of a rare case.
CEN Case Rep. 2012 Nov;1(2):130-131. doi: 10.1007/s13730-012-0025-2. Epub 2012 Jul 13.
2
An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia.
Int J Rheum Dis. 2014 Jul;17(6):679-86. doi: 10.1111/1756-185X.12266. Epub 2014 Jan 28.
3
Clinical characteristics of and relationship between metabolic components and renal function among patients with early-onset juvenile tophaceous gout.
J Rheumatol. 2014 Sep;41(9):1878-83. doi: 10.3899/jrheum.131240. Epub 2014 Aug 1.
4
Febuxostat: a new treatment for hyperuricaemia in gout.
Rheumatology (Oxford). 2009 May;48 Suppl 2:ii15-ii19. doi: 10.1093/rheumatology/kep088.
5
Febuxostat for the treatment of hyperuricaemia in people with gout: a single technology appraisal.
Health Technol Assess. 2009 Oct;13 Suppl 3:37-42. doi: 10.3310/hta13suppl3/06.
6
Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.
Clin Ther. 2009 Nov;31(11):2503-18. doi: 10.1016/j.clinthera.2009.11.033.
7
Safety and efficacy of oral febuxostat for treatment of HLA-B*5801-negative gout: a randomized, open-label, multicentre, allopurinol-controlled study.
Scand J Rheumatol. 2016 Jul;45(4):304-11. doi: 10.3109/03009742.2015.1099729. Epub 2016 Jan 15.
8
An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.
J Clin Rheumatol. 2011 Jun;17(4 Suppl 2):S13-8. doi: 10.1097/RHU.0b013e31821d36cc.
9
Febuxostat: a selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout.
Ann Pharmacother. 2006 Dec;40(12):2187-94. doi: 10.1345/aph.1H121. Epub 2006 Nov 28.
10
A phase 3, multicenter, randomized, allopurinol-controlled study assessing the safety and efficacy of oral febuxostat in Chinese gout patients with hyperuricemia.
Int J Rheum Dis. 2015 Jul;18(6):669-78. doi: 10.1111/1756-185X.12648. Epub 2015 May 27.
引用本文的文献
1
Dosing practices, pharmacokinetics, and effectiveness of allopurinol in gout patients receiving dialysis: a scoping review.
J Nephrol. 2025 Mar 25. doi: 10.1007/s40620-025-02269-7.
2
Clinical features and recurrent attack in gout patients according to serum urate levels during an acute attack.
Korean J Intern Med. 2020 Jan;35(1):240-248. doi: 10.3904/kjim.2018.205. Epub 2019 Jan 28.
本文引用的文献
1
A repeated oral administration study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with impaired renal function in Japan: pharmacokinetic and pharmacodynamic study.
J Clin Rheumatol. 2011 Jun;17(4 Suppl 2):S27-34. doi: 10.1097/RHU.0b013e31821d36f2.
2
Innate immunity conferred by Toll-like receptors 2 and 4 and myeloid differentiation factor 88 expression is pivotal to monosodium urate monohydrate crystal-induced inflammation.
Arthritis Rheum. 2005 Sep;52(9):2936-46. doi: 10.1002/art.21238.
3
Apolipoprotein (apo) E inhibits the capacity of monosodium urate crystals to stimulate neutrophils. Characterization of intraarticular apo E and demonstration of apo E binding to urate crystals in vivo.
J Clin Invest. 1991 Jan;87(1):20-6. doi: 10.1172/JCI114971.
Zotero 插件